# US 2015/0105448 A1 · Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105448 A1
- Document ID: US20150105448A1
- Status: Published application
- Kind: A1
- Application number: 14/577,251
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2002-04-18
- Assignees: RXi Pharmaceuticals Corporation
- Applicants: RXi Pharmaceuticals Corporation
- Inventors: Karina DRUMM; Stefan Hubert SCHLOR; Frank GOHRING
- Web page: https://patentgrep.com/patent/US20150105448A1

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/1709: {from mammals}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A01K 2217/00: Genetically modified animals
- A01K 2217/075: inducing loss of function, i.e. knock out
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/12: in functional genomics, i.e. for the determination of gene function
- C12N 2320/30: Special therapeutic applications
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/16: Ophthalmology
- G01N 2800/28: Neurological disorders
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed.

## Claims

### Claim at position 1

1-90. (canceled)

### Claim 91

A method for the treatment of a disorder of the central nervous system (CNS) and/or the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain and/or the blood-retina barriers.

### Claim 92 (depends on 91)

The method of claim 91, wherein the disorder is an eye disorder.

### Claim 93 (depends on 91)

The method claim 91, wherein said disorder is a disorder of angiogenesis and/or neovascularization.

### Claim 94 (depends on 91)

The method of claim 91, wherein the disorder is a disorder of the retinal pigment epithelium (RPE), neurosensory retina and/or choriodea.

### Claim 95 (depends on 91)

The method of claim 91, wherein said disorder is wet age-related macular degeneration (AMD) or diabetic retinopathy.

### Claim 96 (depends on 91)

The method of claim 91, wherein the composition is effective to be applied outside the retinal region of the blood-retina barrier and cross the blood-retina barrier.

### Claim 97 (depends on 91)

The method of claim 91, wherein the compound is an inhibitor/antagonist of said target gene or gene product.

### Claim 98 (depends on 91)

The method of claim 91, wherein said antagonist/inhibitor inhibits the expression of a gene or the activity of a gene product involved in angiogenesis and/or neovascularization.

### Claim 99 (depends on 91)

The method of claim 91, wherein said antagonist/inhibitor is or is derived from an nucleic acid molecule, polypeptide, antibody, or a ligand binding molecule of said gene or gene product.

### Claim 100 (depends on 91)

The method of claim 91, wherein said antagonist/inhibitor is a ribozyme, antisense or sense nucleic acid molecule to said gene or gene product.

### Claim 101 (depends on 91)

The method of claim 91, wherein said antagonist/inhibitor substantially consists of ribonucleotides.

### Claim 102 (depends on 91)

The method of claim 91, wherein said antagonist/inhibitor comprises substantially a portion of double-stranded oligoribonucleotides (dsRNA).

### Claim 103 (depends on 91)

The method of claim 91, wherein said dsRNA is between 21 and 23 nucleotides in length.

### Claim 104 (depends on 91)

The method of claim 91, wherein the dsRNA molecule contains a terminal 3′-hydroxyl group.

### Claim 105 (depends on 100)

The method of claim 100, wherein the nucleic acid molecule represents an analogue of naturally occurring RNA.

### Claim 106 (depends on 100)

The method of claim 100, wherein the nucleotide sequence of the nucleic acid molecule differs from the nucleotide sequence of said gene or gene product by addition, deletion, substitution or modification of one or more nucleotides.

### Claim 107 (depends on 91)

The method of claim 91, wherein said compound is a nucleic acid molecule or encoded by a nucleic acid molecule and is designed to be expressed in cells of the CNS or eye.

### Claim 108 (depends on 91)

The method of claim 91, wherein the composition is designed for systemic administration or for administration by iontophoresis composition is designed for retrobulbar application or as eye drops

### Claim 109

A pharmaceutical composition effective to cross the blood-retina barrier, wherein the composition comprises a compound capable of modulating a target gene or gene product inside the blood-brain or blood-retina barrier in a therapeutically effective amount.

### Claim 110 (depends on 109)

The pharmaceutical composition of claim 109, wherein the compound is a double-stranded oligoribonucleotide molecule (dsRNA).
